Literature DB >> 2411903

Antigen-antibody analyses in neurocysticercosis.

M Grogl, J J Estrada, G MacDonald, R E Kuhn.   

Abstract

In this report we show that there are 37 polypeptides of larval Taenia solium which react with antibodies from humans with neurocysticercosis. Six of these 37 polypeptides are recognized by antibodies present in the sera of both patients and control individuals. Thus, a minimum of 31 antigens are specific for cysticerci. We describe herein the antigens more frequently recognized by the patients, and the immunoglobulin classes favored in antibody production against each of the cysticercal antigens. It was found that there are 10 major polypeptides with molecular weights of 200,000, 64,000, 62,000-61,000, 53,000, 45,000, 41,000, 36,000-35,000, 30,000 and 16,000 daltons. About 65% of the larval components found to be antigenic are glycoproteins with oligosaccharide chains containing N-acetyl-D-glycosamine and alpha-D-galactose. These results suggest that the sugar moieties of glycoproteins may play a role in the antigenicity of larval T. solium. Based on these observations polypeptides with molecular weights of 64,000, 53,000, and 32,000-30,000 daltons are probably the best choice as sources of antigen to develop an optimal immunological test for the serological diagnosis of neurocysticercosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2411903

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  7 in total

1.  Evaluation of lower molecular mass (20-24 kDa) Taenia solium cysticercus antigen fraction by ELISA and dot blot for the serodiagnosis of neurocysticercosis in children.

Authors:  Jharna Mandal; Pratibha D Singhi; Niranjan Khandelwal; Nancy Malla
Journal:  Parasitol Res       Date:  2008-03-06       Impact factor: 2.289

2.  Specific Taenia crassiceps and Taenia solium antigenic peptides for neurocysticercosis immunodiagnosis using serum samples.

Authors:  E C Bueno; A J Vaz; L D Machado; J A Livramento; S R Mielle
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

3.  Serodiagnosis of human cysticercosis by using antigens from vesicular fluid of Taenia crassiceps cysticerci.

Authors:  E C Bueno; M Snege; A J Vaz; P G Leser
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

4.  Immunoglobulin E and G4 antibodies in cysticercosis.

Authors:  J A Short; D C Heiner; R L Hsiao; F L Andersen
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

5.  Immunotherapy for porcine cysticercosis: implications for prevention of human disease. Cysticercosis Working Group in Peru.

Authors:  C A Evans; A E Gonzalez; R H Gilman; M Verastegui; H H Garcia; A Chavera; J B Pilcher; V C Tsang
Journal:  Am J Trop Med Hyg       Date:  1997-01       Impact factor: 2.345

6.  Use of Taenia crassiceps cysticercus antigen preparations for detection of antibodies in cerebrospinal fluid samples from patients with neurocysticercosis (Taenia solium).

Authors:  Alessandra Xavier Pardini; Regina Helena Peralta; Adelaide José Vaz; Luis dos Ramos Machado; José Mauro Peralta
Journal:  Clin Diagn Lab Immunol       Date:  2002-01

Review 7.  Immunological and molecular diagnosis of cysticercosis.

Authors:  Silvia Rodriguez; Patricia Wilkins; Pierre Dorny
Journal:  Pathog Glob Health       Date:  2012-09       Impact factor: 2.894

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.